About
Clinical outcome upon infection with SARS-CoV-2 ranges from silent infection to lethal COVID-19. We identified autosomal-recessive or autosomal-dominant deficiencies of genes in the type I IFN circuit in 23 patients (3.5%) 17 to 77 years of age. We showed that inborn errors of TLR3- and IRF7- dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection.
Presenters
1617008412-0c8b9a67eb545076
Qian Zhang
Presenter
Qian Zhang was trained as a pediatrician after she graduated from the Medical School of Fudan University in Shanghai. She joined Dr. Helen ’u’s lab at the NIH as a postdoc to be trained in scientific research in the field of inborn errors of immunity. Since 2017, Qian Zhang first joined as a visiting scholar but soon as a group leader at the lab of Prof. Jean-Laurent Casanova and Laurent ’bel’s lab, and focuses her research in human genetics of respiratory viral infections.
1618215332-cf42d9436755b4e7
Jonny Peter
Moderator
A/PROF JONNY PETER is a physician, specialised in internal medicine at the University of Cape Town, South Africa. In February 2016, Jonathan was registered with the HPCSA as the first adult allergologist in South Africa, and is Head of the Division of Allergology and Clinical Immunology at Groote Schuur Hospital, University of Cape Town and the Allergy and Immunology unit, UCT Lung Institute. Current clinical and research interests include: i) immune-mediated adverse drug reactions ii) urticaria and angioedema, as well as the intersection between COVID19 and immunogenomic pathways associated with Angioedema iii) primary immunodeficiencies, and iv) the aerobiology of South Africa. Jonathan has over 80 publications in high impact factor journals, and H-index of 36. His research work is supported by international and local grant funding from the NIH, EDCTP, SA NRF and MRC.
Register To Watch Recording
Full name*
Email Address*
Affiliation/Institution*
Country*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.